Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy

Angiogenesis has not been extensively studied in Parkinson’s disease (PD) despite being associated with other neurodegenerative disorders. Post-mortem human brain tissues were obtained from subjects with pathologically confirmed Parkinson’s disease (PD) and progressive supranuclear palsy (PSP), a rapidly progressing Parkinsonian-like disorder. Tissues were also obtained from subjects with incidental Lewy body disease (iLBD) who had Lewy bodies in the substantia nigra pars compacta (SNpc) but had not been diagnosed with PD, and age-matched controls without Lewy body pathology. The SNpc, putamen, locus ceruleus (LC) and midfrontal cortex were examined for integrin αvβ3, a marker for angiogenesis, along with vessel number and activated microglia. All parkinsonian syndromes had greater αvβ3 in the LC and the SNpc, while only PD and PSP subjects had elevated αvβ3 in the putamen compared to controls. PD and PSP subjects also had increases in microglia number and activation in the SNpc suggesting a link between inflammation and clinical disease. Microglia activation in iLBD subjects was limited to the LC, an area involved at an early stage of PD. Likewise, iLBD subjects did not differ from controls in αvβ3 staining in the putamen, a late area of involvement in PD. The presence of αvβ3 reactive vessels in PD and its syndromes is indicative of newly created vessels that have not likely developed the restrictive properties of the blood brain barrier. Such angiogenic vessels could contribute to neuroinflammation by failing to protect the parenchyma from peripheral immune cells and inflammatory or toxic factors in the peripheral circulation.

[1]  E Bertrand,et al.  Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. , 1997, Folia neuropathologica.

[2]  G. Lynch,et al.  Integrin Subunit Gene Expression Is Regionally Differentiated in Adult Brain , 1999, The Journal of Neuroscience.

[3]  R. Sidman,et al.  Treatment of hypoxia‐induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  M. Horton Vitronectin receptor: tissue specific expression or adaptation to culture? , 1990, International journal of experimental pathology.

[5]  P. Rakic,et al.  Three‐dimensional counting: An accurate and direct method to estimate numbers of cells in sectioned material , 1988, The Journal of comparative neurology.

[6]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[7]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Masanori Ichise,et al.  In vivo imaging of microglial activation using a peripheral benzodiazepine ligand, 11C-CB148 and animal PET following ethanol injury in rat striatum: A comparison with 11C-PK11195 , 2007 .

[9]  A. Vagnucci,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Alzheimer's Disease and Angiogenesis , 2022 .

[10]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  M. Matsunaga,et al.  Effects of benserazide on l-DOPA-derived extracellular dopamine levels and aromatic l-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats , 2003 .

[12]  I. Campbell,et al.  The Extracellular Matrix and Cytokines Regulate Microglial Integrin Expression and Activation1 , 2003, The Journal of Immunology.

[13]  Y. Michotte,et al.  Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat , 2001, Journal of Neural Transmission.

[14]  W. Streit Microglial senescence: does the brain's immune system have an expiration date? , 2006, Trends in Neurosciences.

[15]  N. Hattori,et al.  Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease , 2007, Experimental Neurology.

[16]  D. Dione,et al.  Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. , 2008, Journal of applied physiology.

[17]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[18]  Max Gassmann,et al.  Astrocyte responses to injury: VEGF simultaneously modulates cell death and proliferation. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[19]  S. Dedhar,et al.  Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue , 1991, Journal of Neuroimmunology.

[20]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[21]  D. Dickson,et al.  Microglial Activation Parallels System Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Journal of neuropathology and experimental neurology.

[22]  Y. Mizuno,et al.  Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease , 2006, Neuroreport.

[23]  H. Braak,et al.  Neuroanatomy and pathology of sporadic Parkinson's disease. , 2008, Advances in anatomy, embryology, and cell biology.

[24]  Ling Wei,et al.  Collateral Growth and Angiogenesis Around Cortical Stroke , 2001, Stroke.

[25]  Sanjiv S Gambhir,et al.  Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. , 2008, Radiology.

[26]  D. Dickson,et al.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank , 2003, Movement disorders : official journal of the Movement Disorder Society.

[27]  J. Nyengaard,et al.  Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia , 2006, The Journal of Neuroscience.

[28]  H. Gendelman,et al.  Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.

[29]  Ivan Damjanov,et al.  Blood Vessels , 2004 .

[30]  D. Bennett,et al.  LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.

[31]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[32]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[33]  F. Carraro,et al.  Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.

[34]  J. Kordower,et al.  Age and region‐specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure in monkeys , 2008, Glia.

[35]  David A. Bennett,et al.  Decision Rules Guiding the Clinical Diagnosis of Alzheimer’s Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort Study , 2006, Neuroepidemiology.

[36]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[37]  B. Jin,et al.  The role of neuroinflammation on the pathogenesis of Parkinson's disease. , 2010, BMB reports.

[38]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[39]  M. Graeber,et al.  Controversies over the staging of α-synuclein pathology in Parkinson’s disease , 2008, Acta Neuropathologica.

[40]  P. Carvey,et al.  Evidence of angiogenic vessels in Alzheimer’s disease , 2009, Journal of Neural Transmission.

[41]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.

[42]  P. Carvey,et al.  6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.

[43]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[44]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[45]  J. Newcombe,et al.  Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter , 2010, Neuroscience Letters.

[46]  P S Whitton,et al.  Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.

[47]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[48]  S. Rocha,et al.  Regulation of gene expression by hypoxia. , 2008, The Biochemical journal.

[49]  E. Hirsch,et al.  Blood vessels and parkinsonism. , 2004, Frontiers in bioscience : a journal and virtual library.

[50]  P. Carvey,et al.  The blood–brain barrier in neurodegenerative disease: a rhetorical perspective , 2009, Journal of neurochemistry.

[51]  J. Folkman Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[52]  Rakesh K Jain,et al.  Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.

[53]  P. Grammas,et al.  Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[54]  M. Cenci,et al.  Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[55]  D. McDonald,et al.  Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. , 2004, The American journal of pathology.

[56]  J. Geiger,et al.  Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum , 2008, Journal of neurochemistry.

[57]  F. Fadda,et al.  Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.

[58]  E. Hirsch,et al.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian , 2005, Journal of Neural Transmission.

[59]  D. Dickson,et al.  Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.

[60]  A. Drzezga,et al.  In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer’s disease , 2006, Angiogenesis.

[61]  D. Paik,et al.  Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm , 2004, Experimental & Molecular Medicine.

[62]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[63]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[64]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[65]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[66]  J. Frank,et al.  Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? , 2004, Journal of the Neurological Sciences.

[67]  D. Bennett,et al.  The neuropathology of older persons with and without dementia from community versus clinic cohorts. , 2009, Journal of Alzheimer's disease : JAD.

[68]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[69]  B. Jenkins,et al.  The blood–brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates—Evidence from in vivo neuroimaging studies , 2009, Neurobiology of Disease.

[70]  S. Leurgans,et al.  Neurodegenerative basis of age-related cognitive decline , 2010, Neurology.

[71]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[72]  C. ffrench-Constant,et al.  Expression of αvβ3 and αvβ8 integrins during oligodendrocyte precursor differentiation in the presence and absence of axons , 1997, Glia.

[73]  W. Lukiw,et al.  Angiogenic signaling in Alzheimer's disease , 2004, Neuroreport.

[74]  H. Braak,et al.  Reply to “Controversies over the staging of α-synuclein pathology in Parkinson’s disease” , 2008, Acta Neuropathologica.

[75]  H. Gendelman,et al.  Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease , 2010, The Journal of Immunology.

[76]  P. Lantos,et al.  Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases , 2007, Journal of Neural Transmission.

[77]  D. Dickson,et al.  Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease , 2008, Acta Neuropathologica.

[78]  D. McDonald,et al.  Markers for Microscopic Imaging of Lymphangiogenesis and Angiogenesis , 2008, Annals of the New York Academy of Sciences.

[79]  S. Karlik,et al.  VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE , 2009, Journal of Neuroimmunology.

[80]  P. Brooks,et al.  Role of integrins in angiogenesis. , 1996, European journal of cancer.

[81]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[82]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.